David Wild

Toronto

Pharma and Biotech Reporter at In Vivo

I cover the world of pharma and biotech for In Vivo @invivonow, a @Citeline publication. I also play in a Grateful Dead cover band. Please DM with story ideas.

Articles

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

4 days ago | insights.citeline.com | David Wild

Finding The Fire: AltruBio’s Novel Approach To Autoimmune DiseaseCEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.
Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

4 days ago | insights.citeline.com | David Wild

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic SpaceA look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

6 days ago | insights.citeline.com | David Wild

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech LeadershipMetsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

6 days ago | insights.citeline.com | David Wild

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic BiologyThe UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Leaders At The Frontier: Conversations From SynBioBeta 2025

1 week ago | insights.citeline.com | David Wild

Leaders At The Frontier: Conversations From SynBioBeta 2025Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
ML-Assisted Genetic Risk Score Predicts GLP-1 Toxicity

2 weeks ago | insights.citeline.com | David Wild

ML-Assisted Genetic Risk Score Predicts GLP-1 ToxicityPhenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum

2 weeks ago | insights.citeline.com | David Wild

How Vir CEO Marianne De Backer Is Rebuilding Commercial MomentumFrom billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership. Marianne De Backer Has Guided Vir Biotechnology Through A Pipeline Pivot • Source: Shutterstock
AI In Drug Discovery: The Patent Implications

2 weeks ago | insights.citeline.com | David Wild

AI In Drug Discovery: The Patent ImplicationsA Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag. AI in Drug Discovery Complicates Patentability (Shutterstock)
Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

3 weeks ago | insights.citeline.com | David Wild

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review ProcessThe FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.
Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

1 month ago | insights.citeline.com | David Wild

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic PatienceAfter revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.